Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$233.80
-6.1%
$236.80
$96.09
$260.19
$12.81B0.61.14 million shs804,605 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$85.89
-4.7%
$69.76
$42.09
$93.42
$17.66B0.954.64 million shs6.38 million shs
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$31.47
$31.24
$19.05
$32.56
$3.85B0.741.88 million shs1.35 million shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$24.84
+0.9%
$23.45
$13.39
$27.72
$12.30B1.684.33 million shs3.88 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-6.09%-4.30%-5.09%+31.27%+108.10%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-4.75%+11.27%+27.43%+15.15%+86.80%
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
0.00%+0.06%+0.41%+26.18%+45.49%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+0.82%-0.42%+8.24%+7.47%+67.81%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$233.80
-6.1%
$236.80
$96.09
$260.19
$12.81B0.61.14 million shs804,605 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$85.89
-4.7%
$69.76
$42.09
$93.42
$17.66B0.954.64 million shs6.38 million shs
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$31.47
$31.24
$19.05
$32.56
$3.85B0.741.88 million shs1.35 million shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$24.84
+0.9%
$23.45
$13.39
$27.72
$12.30B1.684.33 million shs3.88 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-6.09%-4.30%-5.09%+31.27%+108.10%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-4.75%+11.27%+27.43%+15.15%+86.80%
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
0.00%+0.06%+0.41%+26.18%+45.49%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+0.82%-0.42%+8.24%+7.47%+67.81%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.95
Moderate Buy$259.0510.80% Upside
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.83
Moderate Buy$92.908.16% Upside
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
2.56
Moderate Buy$32.001.68% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.77
Moderate Buy$28.5514.94% Upside

Current Analyst Ratings Breakdown

Latest CPRX, BBIO, AXSM, and ELAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Reiterated RatingBuy$290.00
7/7/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetOutperform$302.00 ➝ $304.00
6/29/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Reiterated RatingOverweight
6/18/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Boost Price TargetBuy$31.00 ➝ $32.00
6/17/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetBuy$275.00 ➝ $300.00
6/16/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Lower Price TargetOutperform$106.00 ➝ $96.00
6/15/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
UpgradeStrong-Buy
6/11/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Reiterated RatingBuy$380.00
6/11/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
UpgradeReduceOverweight
6/4/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Reiterated RatingBuy
6/3/2026
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
UpgradeBuy (B-)Buy (B)
(Data available from 7/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$638.50M18.84N/AN/A$1.75 per share133.60
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$502.08M33.51N/AN/A($10.77) per share-7.97
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$596.96M6.45$2.92 per share10.77$7.76 per share4.06
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.72B2.63$2.34 per share10.61$13.18 per share1.88
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$183.17M-$3.73N/A50.06N/A-26.59%-267.16%-28.53%8/3/2026 (Estimated)
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.74N/A660.69N/A-124.42%N/A-65.81%8/4/2026 (Estimated)
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$214.33M$1.7418.0910.220.9637.08%35.76%31.31%8/5/2026 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$232M-$0.50N/A20.361.61-4.95%7.42%3.66%8/5/2026 (Estimated)

Latest CPRX, BBIO, AXSM, and ELAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$0.48N/AN/AN/A$155.79 millionN/A
8/5/2026Q2 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.28N/AN/AN/A$1.31 billionN/A
8/4/2026Q2 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.64N/AN/AN/A$220.21 millionN/A
8/3/2026Q2 2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.8520N/AN/AN/A$221.92 millionN/A
5/7/2026Q1 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.70-$0.84-$0.14-$0.84$178.07 million$194.52 million
5/6/2026Q1 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.34$0.40+$0.06$0.11$1.28 billion$1.37 billion
5/4/2026Q1 2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.85-$1.26-$0.41-$1.26$191.10 million$191.20 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.27
1.39
1.32
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
1.52
1.48
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
N/A
7.10
6.84
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.60
2.16
1.12

Institutional Ownership

CompanyInstitutional Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
79.22%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%

Insider Ownership

CompanyInsider Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
20.60%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
10.40%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
1.14%
CompanyEmployeesShares OutstandingFree FloatOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
38051.46 million40.86 millionOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400195.86 million167.99 millionOptionable
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
80122.42 million109.69 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,400499.45 million493.76 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$233.80 -15.15 (-6.09%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$232.64 -1.16 (-0.50%)
As of 07/10/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$85.89 -4.28 (-4.75%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$87.36 +1.47 (+1.72%)
As of 07/10/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Catalyst Pharmaceuticals stock logo

Catalyst Pharmaceuticals NASDAQ:CPRX

$31.47 0.00 (0.00%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$31.48 +0.02 (+0.05%)
As of 07/10/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$24.84 +0.22 (+0.88%)
Closing price 07/10/2026 03:59 PM Eastern
Extended Trading
$24.82 -0.02 (-0.06%)
As of 07/10/2026 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.